NASDAQ:AMRN - Amarin Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $20.12 +0.83 (+4.30 %) (As of 10/16/2018 04:00 PM ET)Previous Close$19.29Today's Range$19.34 - $20.4652-Week Range$2.35 - $21.05Volume13.40 million shsAverage Volume5.82 million shsMarket Capitalization$4.76 billionP/E Ratio-77.16Dividend YieldN/ABeta0.32 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland. Receive AMRN News and Ratings via Email Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:AMRN CUSIPN/A Webwww.amarincorp.com Phone353-1669-9020 Debt Debt-to-Equity Ratio-1.25 Current Ratio1.43 Quick Ratio1.13 Price-To-Earnings Trailing P/E Ratio-77.16 Forward P/E Ratio-47.90 P/E GrowthN/A Sales & Book Value Annual Sales$181.10 million Price / Sales32.48 Cash FlowN/A Price / CashN/A Book Value($0.33) per share Price / Book-60.97 Profitability EPS (Most Recent Fiscal Year)($0.25) Net Income$-67,860,000.00 Net Margins-46.31% Return on EquityN/A Return on Assets-48.98% Miscellaneous Employees241 Outstanding Shares292,320,000Market Cap$4.76 billion Amarin (NASDAQ:AMRN) Frequently Asked Questions What is Amarin's stock symbol? Amarin trades on the NASDAQ under the ticker symbol "AMRN." How were Amarin's earnings last quarter? Amarin Co. plc (NASDAQ:AMRN) announced its earnings results on Wednesday, August, 1st. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.03. The biopharmaceutical company had revenue of $52.64 million for the quarter, compared to the consensus estimate of $54.88 million. Amarin's revenue was up 16.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.04) EPS. View Amarin's Earnings History. When is Amarin's next earnings date? Amarin is scheduled to release their next quarterly earnings announcement on Wednesday, November 7th 2018. View Earnings Estimates for Amarin. What price target have analysts set for AMRN? 4 brokerages have issued 12 month price targets for Amarin's stock. Their forecasts range from $15.00 to $35.00. On average, they expect Amarin's share price to reach $23.75 in the next year. This suggests a possible upside of 18.0% from the stock's current price. View Analyst Price Targets for Amarin. What is the consensus analysts' recommendation for Amarin? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amarin. What are Wall Street analysts saying about Amarin stock? Here are some recent quotes from research analysts about Amarin stock: 1. HC Wainwright analysts commented, "Our price target of $20 is based on equally weighted average of: (a) $19.9/share, as a 20x multiple of taxed and diluted FY23 GAAP EPS of $3.69 discounted back to and (b) an NPV of $20.8/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by generics and/or OTC supplements beyond our model." (9/25/2018) 2. Cantor Fitzgerald analysts commented, "We think the peak sales potential of Vascepa is under appreciated. Therefore, upwards earnings revisions to levels not reflected in consensus should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $10." (9/24/2018) 3. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (8/8/2018) Are investors shorting Amarin? Amarin saw a increase in short interest in September. As of September 28th, there was short interest totalling 16,229,338 shares, an increase of 33.6% from the September 14th total of 12,145,010 shares. Based on an average daily volume of 40,089,798 shares, the days-to-cover ratio is presently 0.4 days. Approximately 5.6% of the company's shares are sold short. View Amarin's Current Options Chain. Who are some of Amarin's key competitors? Some companies that are related to Amarin include Mylan (MYL), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Perrigo (PRGO), Beigene (BGNE), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY) and Valeant Pharmaceuticals (VRX). Who are Amarin's key executives? Amarin's management team includes the folowing people: Mr. John F. Thero, Chief Exec. Officer, Pres and Director (Age 57)Mr. Michael W. Kalb, Chief Financial Officer and Sr. VP (Age 47)Dr. Steven B. Ketchum, Chief Scientific Officer, Pres of R&D and Sr. VP (Age 53)Mr. Joseph T. Kennedy J.D., Chief Compliance Officer, Exec. VP of Strategic Initiatives, Gen. Counsel and Sec. (Age 50)Ms. Elisabeth Schwartz, Sr. Director of Investor Relations Who are Amarin's major shareholders? Amarin's stock is owned by many different of institutional and retail investors. Top institutional investors include State of New Jersey Common Pension Fund D (0.07%). Company insiders that own Amarin stock include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin. Which institutional investors are buying Amarin stock? AMRN stock was purchased by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D. View Insider Buying and Selling for Amarin. How do I buy shares of Amarin? Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amarin's stock price today? One share of AMRN stock can currently be purchased for approximately $20.12. How big of a company is Amarin? Amarin has a market capitalization of $4.76 billion and generates $181.10 million in revenue each year. The biopharmaceutical company earns $-67,860,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Amarin employs 241 workers across the globe. What is Amarin's official website? The official website for Amarin is http://www.amarincorp.com. How can I contact Amarin? Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected] MarketBeat Community Rating for Amarin (NASDAQ AMRN)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 550 (Vote Outperform)Underperform Votes: 333 (Vote Underperform)Total Votes: 883MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/16/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?